← Back to patent-cliff list
CAS 612-60-2
7-methylquinoline
Codes: LINSI-005
Application context (from source-drug indications)
甲状腺疾病Linsitinib甲状腺相关性眼病Linsitinib慢性淋巴细胞性甲状腺炎Linsitinib突眼症LinsitinibMultiple myelomaLinsitinib唇肿瘤Linsitinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Linsitinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
7-methylquinoline→phenyllithium→7-methyl-2-phenylquinoline→2-phenylquinoline-7-carbaldehyde→2-chloropyrazine→(3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methanol→isoindoline-1,3-dione→2-((3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methyl)isoindoline-1,3-dione→(3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methanamine→3-methylenecyclobutane-1-carboxylic acid→N-((3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methyl)-3-methylenecyclobutane-1-carboxamide→7-(8-chloro-3-(3-methylenecyclobutyl)imidazo[1,5-a]pyrazin-1-yl)-2-phenylquinoline→3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-(hydroxymethyl)cyclobutan-1-ol→3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)cyclobutan-1-one→(1s,3s)-3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.